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Abstract
The renin-angiotensin system, in both its circulating and local tissue roles, is 
intertwined with multiple other regulatory and signalling mechanisms in various 
tissues and organ systems. It plays a central role in the normal regulation of arte-
rial blood pressure and in the development of hypertension, which is an immense 
global public health burden and a crucial modifiable risk factor in the development 
of cardiovascular diseases. The renin-angiotensin system plays also important roles 
in a range of other clinical conditions such as heart failure, kidney failure, diabe-
tes mellitus and others. Therapeutic interventions within the renin-angiotensin 
system include the use of medications such as angiotensin-converting enzyme 
inhibitors and angiotensin receptor antagonists, which are well established and 
have been invaluable as clinically effective tools during many years of practical use. 
Additionally, numerous other therapeutic approaches targeting components of the 
renin-angiotensin system have been developed or are currently in development. 
This chapter will discuss details of the roles of this system in the most relevant 
clinical conditions.
Keywords: renin-angiotensin system, hypertension, heart failure,  
angiotensin-converting enzyme inhibitors, diabetes mellitus
1. Introduction
The renin-angiotensin system (RAS), in both its circulating and local tissue 
roles, is intertwined with multiple other regulatory and signalling mechanisms 
in various tissues and organ systems. It is thereby involved in a number of clini-
cal disorders with complex pathophysiological mechanisms. This chapter aims at 
providing a brief overview of the most relevant conditions in clinical practice in 
which the RAS is important when considering its pathophysiological or therapeutic 
significance.
2. RAS in hypertension
Systemic arterial hypertension is the most crucial global modifiable risk 
factor for morbidity and mortality and clearly connected to cardiovascular 
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disease development [1]. The RAS plays a central role in the normal regulation 
of blood pressure and in the development of hypertension [2]. RAS regulates 
blood pressure through its effector protein angiotensin II (Ang II), which causes 
the constriction of the efferent arteriole in the kidney glomerulus, as well as the 
vasoconstriction of arterioles in peripheral circulation [3]. In addition to the 
above, RAS achieves its effects by stimulating the secretion of aldosterone by 
adrenal glands and vasopressin by the posterior pituitary, which, through the 
synergistic effect of water retention and sodium absorption, ensures the stability 
or increase of the intravascular volume [3]. Abnormal RAS activity is present 
in conditions such as hypertension and diabetes, which causes slow, continuous 
damage to the renal parenchyma and leads to the development of chronic kidney 
disease (CKD) [4, 5].
The pathophysiology of essential hypertension and other types of hypertension 
is extremely complex and not fully elucidated, with the RAS contributing only in 
part to the multifactorial pathophysiological mechanisms [1]. There is a pathophysi-
ological interplay between the RAS, endothelial function/dysfunction, the role 
of the sympathetic nervous system, natriuretic peptides, inflammation and the 
immune system [1]. A dysfunction in the factors that contribute to blood pressure 
control may lead to the development of increases in mean blood pressure [1]. The 
genetic background/predisposition is of course very relevant. Furthermore, the 
RAS may play a completely different role depending on the type of hypertension. 
For instance, in primary aldosteronism, the most common type of secondary hyper-
tension, there is an inappropriate increase in aldosterone synthesis in the setting of 
low plasma renin [6].
In addition to its main hemodynamic, fluid volume and vascular tone-changing 
effects, RAS can participate in stimulating immune cell infiltration, inflammation 
and fibrosis that is present in conditions such as renal ischemia, myocardial infarc-
tion and systemic hypertension [7]. Because of the connection of angiotensin II to 
endothelial dysfunction, proinflammatory and profibrotic actions and oxidative 
stress, it is associated with renal, cardiac and vascular injury and thereby directly 
linked to target organ damage in hypertension [7].
Besides the most largely know effector arm of the RAS, which includes 
angiotensin II and the angiotensin II type 1 receptor (AT1R), the RAS system 
is much more complex and features other important components, including 
angiotensin-(1–7) (Ang-(1–7), which exerts opposite effects than angiotensin 
II—it leads to vasodilation, and it has antifibrotic and antiproliferative effects 
[8]. Angiotensin-(1–7) is being extensively studied, including for its potential 
antihypertensive effects. Its potentially favourable cardiovascular actions are 
elicited through Mas G protein-coupled receptors that are expressed in various 
tissues essential to blood pressure regulation such as the brain, kidneys, blood 
vessels and heart [9]. However, the clinical potential and role of angiotensin-(1–7) 
in the pathophysiology and treatment is not yet clear because of a lack of adequate 
clinical studies and data [9].
From a therapeutic standpoint, there are several important groups of pharma-
cological agents targeting the RAS in hypertension. These include already clinically 
well-established antihypertensive drugs such as inhibitors of the angiotensin-
converting enzyme (ACE inhibitors), AT1R blockers or direct renin inhibitors [2]. 
However, novel potential drugs targeting the RAS are also being developed, includ-
ing agents seeking to upregulate the ACE2/angiotensin-(1–7)/Mas axis—coun-
teracting the unwanted actions of the ACE/angiotensin II/AT1R axis—or agents 
such as new small molecule inhibitors, recombinant ACE2 protein, as well as gene 
therapy suppressing angiotensinogen at the RNA level [2].
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3. Role in heart failure
3.1 Introduction
Heart failure is a progressive condition defined by the inability of the heart to 
pump enough blood to meet the body requirements for nutrients and oxygen.
It develops when the heart fails to pump enough blood to meet the requirements 
of metabolizing tissues, which is caused by conditions like ischaemic heart disease, 
arrhythmias, etc., and produces different symptoms and signs. Some of the symp-
toms and signs include the following: exertional dyspnoea and/or dyspnoea at rest, 
orthopnoea, acute pulmonary oedema, chest pain, tachycardia, fatigue and weak-
ness, distention of neck veins, rales, wheezing, S gallop or pulsus alternans, etc. [7].
Heart failure is one of the most challenging pathophysiologic states with increas-
ing prevalence in the Western world, affecting 1–2% of the total population [10].
The neurohumoral basis of heart failure is complex and includes interaction 
between components of the renin-angiotensin-aldosterone system (RAAS), the 
sympathetic nervous system and counterregulatory mediators (i.e., the natriuretic 
peptides).
Activation of neurohumoral mechanisms (i.e., the renin-angiotensin-aldoste-
rone system) initially improves cardiac output, but despite this, counterregulatory 
mechanisms finally lead to heart failure syndrome with different signs and symp-
toms [11].
3.1.1 The neurohumoral pathophysiology of heart failure
The renin-angiotensin-aldosterone system (RAAS) plays a major role in the 
pathogenesis of heart failure, and the impact of treatment that targets RAAS is 
significant.
Figure 1. 
A summary of the key pathogenesis of RAAS in heart failure. RAAS, renin-angiotensin-aldosterone system; 
ADH, antidiuretic hormone.
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The neurohumoral basis of heart failure includes activation of RAAS by 
renal hypoperfusion (caused by hypotension or hypovolemia) and sympathetic 
 activation [12].
Production of angiotensin II leads to vasoconstriction of arterioles and an 
increase in blood pressure, leads to antidiuretic hormone secretion, and stimulates 
the release of aldosterone and consequently salt and water retention [12] (Figure 1).
All of the above temporarily improve cardiac output but finally propagate the 
heart failure syndrome via overwhelming the opposing vasodilators and natriuretic 
mediators (i.e., A-type natriuretic peptide and B-type natriuretic peptide) which 
are mainly secreted form heart in response to the degree of ventricular stretch [13].
An imbalance between regulatory and counterregulatory mechanisms is the 
major pathophysiological target in heart failure treatment.
Therefore drugs that modulate RAAS (i.e., ACE inhibitors, beta-blockers, angio-
tensin receptor blockers and mineralocorticoid receptor antagonists) represent 
the core of treatment augmented by angiotensin receptor neprilysin inhibitors as a 
novel therapy [14].
4. Role in kidney failure
Chronic kidney disease (CKD) is a disease whose prevalence is constantly 
increasing in the elderly in the current, modern age [15]. CKD has multiple causes, 
where different organ dysfunctions lead to the reduction of the glomerular filtra-
tion rate, a disorder of excretory and endocrine function of the kidney and a 
significant diminishment of quality of life of such patients [16, 17]. End-stage 
renal failure, where glomerular filtration rate falls to less than 15 ml/min, requires 
treating the patient suffering from CKD with haemodialysis, which is a process in 
which blood is filtered through a semipermeable membrane, intended to replace the 
excretory function of the kidney [18]. Considering the high costs of treatment of 
patients with CKD, much research has been dedicated to studying the pathophysi-
ological mechanisms that contribute to its development and exacerbation with the 
intention of developing new medications and procedures in an attempt to slow 
down the increase in the prevalence of patients with CKD. Abnormal activity of the 
renin-angiotensin system (RAS), regardless of the primary cause of CKD, has an 
immense value in the results of many studies [19].
In patients with CKD, RAS activity is increased in the central and periph-
eral circulation, which is indirectly confirmed by the fact that the activity and 
expression of the angiotensin-converting enzyme (ACE) linearly increases as the 
glomerular filtration rate decreases in patients with CKD [20]. Although ACE is 
the main enzyme that leads to RAS activation in patients with CKD by convert-
ing angiotensin I (Ang I) into angiotensin II, certain studies have shown that in 
particular types of acute renal failure, such as the one caused by aristolochic acid, 
there is a more significant RAS activation through chymases and a relatively mild 
ACE activation [21]. Chymase inhibition causes the slowing of the progression 
of fibrotic and inflammatory changes in the renal parenchyma, which makes it 
possible to talk about the synergistic effect of ACE and chymases in the activa-
tion of RAS effectors [21]. The role of chymase is also crucial for RAS activation 
in patients with stage five CKD treated with haemodialysis [22]. Considering the 
lower-than-normal levels of ACE and high chymase levels in such patients than 
those in patients with the same stage of CKD who are undergoing conservative 
treatment, it is clear that in such patients, the high levels of angiotensin in the renal 
parenchyma are a consequence of the increased chymase activity [22]. Increased 
chymase and angiotensin II activity leads to faster development of renal fibrosis 
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in patients treated with haemodialysis than that in patients with the same stage of 
CKD who are not treated with dialysis [22].
According to new findings, nearly all RAS components may have a big effect on 
the development of CKD and its predisposing factors, such as hypertension. The 
activity of the prorenin receptors (PRR), which is found in the collecting duct cells 
of the kidney and increases the affinity of renin for angiotensinogen, is significant 
for RAS activation [23]. PRR blockade in animal models causes the decrease of 
RAS activity, which indirectly decreases levels of proteinuria, macroscopic signs 
of interstitial fibrosis and renal fibrosis. Although the increased activity of the 
systemic RAS plays a large role in the development of CKD, new findings place 
greater emphasis on the role of the local RAS in the renal and brain parenchyma 
and their synergistic effects. Prolonged activation of the local RAS in the renal 
parenchyma causes the production of inflammatory cytokines IL-6 and TNF-
alpha, which lead to the infiltration of inflammatory cells into renal tissue, tissue 
damage and fibrosis [24] (Table 1).
Recent studies have identified the Wnt/β catenin signalling pathway as the 
main pathway for expression of RAS components in renal tissue, and its blockade 
in animal models of CKD was connected to significant clinical improvement and 
reduction of proteinuria and creatininaemia [25]. The Wnt/β catenin signalling 
pathway is the main pathway for RAS expression in the hypothalamic paraventricu-
lar nucleus which indirectly affects the renal tissue RAS through activation of the 
sympathetic nervous system [26]. Blocking the central Wnt/β catenin signalling 
pathway leads to the inhibition of expression of the renal RAS components and to 
the slowing of the progression of renal fibrosis; it is thus clear that in the tissue, 
local RAS is regulated by the central nervous system [5, 26]. Inhibition of RAS 
through intraventricular injection of losartan leads to a decrease in peripheral 
sympathetic nervous system activity and renal RAS activity, which potentially 
makes the sympathetic nervous system one of the possible pathways of communi-
cation between renal RAS and brain RAS [5]. In animal models of CKD, where a 
strong expression of RAS components was noticed after incubation of renal cells 
with inhibitors of the Wnt/β catenin signalling pathway, there is mainly a reduced 
expression of profibrotic factors in the renal parenchyma. In one such model, posi-
tive feedback was noticed between RAS and the Wnt/β catenin signalling pathway, 
where angiotensin II increases the expression of proteins of that signalling pathway, 
which is probably also the mechanism used by the central and circulating RAS to 
stimulate the activity of local RAS [25].
The role of the Wnt/β catenin signalling pathway in RAS activation and local 
fibrosis is also confirmed by research done on its inhibitors. The Klotho gene, which 
plays a significant role in slowing the process of ageing, encodes the protein which 
inhibits the components of the Wnt/β catenin signalling pathway [27]. In renal tissue 
of animal models of CKD, the Klotho level is inversely associated with the levels of 
RAS components, and the Klotho expression level showed a negative correlation with 
the degree of renal fibrosis [27]. Experimental studies on animal models that proved 
the effect of vitamin D on the decreased level of CKD and renal fibrosis measure an 
increased Klotho level, decreased activation of the Wnt/β catenin signalling pathway 
and low tissue RAS activity in in vitro conditions [28]. Multiple experimental studies 
have demonstrated the connection between the Wnt/β catenin signalling pathway 
and harmful RAS activation in CKD and renal fibrosis, which paves the way for 
new research with the aim of finding efficient medications that would slow the 
development and progression of CKD by affecting the above components [24, 26].
Local renal RAS may be activated by the effects of free radicals, which stimulate 
the expression of RAS components at the molecular level of signalling pathways. 
The above factor is one of the main mechanisms examined in harmful RAS 
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activation in diabetic nephropathy, which is one of the leading causes of CKD 
[5]. The effect of free radicals on the development of CKD was demonstrated 
in studies examining strong antioxidants, such as melatonin. The application 
of melatonin in animal models of CKD leads to a reduced expression of all RAS 
components, decreased levels of markers of interstitial fibrosis and increased 
expression of antioxidant enzymes, such as superoxide dismutase [29]. The role 
of RAS in CKD has also been examined at the level of angiotensin receptors. 
Angiotensin II mainly produces its effect by activating the AT1 receptor, through 
which it causes vasoconstriction and has a proinflammatory and profibrotic 
effect on renal parenchyma. In addition to the AT1 receptor, there is also the AT2 
receptor, which is presumed to have a vasodilatory and renoprotective effect. In 
experiments on animal models of CKD using resveratrol, which is a selective AT1 
receptor antagonist and AT2 receptor agonist, increased expression of antioxidant 
Component of RAS system 
whose activation or 
inhibition is involved in the 
development of CKD
Explanation of mechanism References (author, year and 
title of study)
Prorenin receptor placed in 
collecting duct cells of kidney
PRR increases the affinity 
of prorenin and renin for 
angiotensin, and blockade of this 
receptor decreases activity of 
components of RAS and reduces 
laboratory markers of CKD
[23] (Fang et al., 2018, Role of 
(pro)renin receptor in albumin 
overload-induced nephropathy 
in rats)
Wnt/β catenin signalling 
pathway as the main pathway 
for expression of RAS 
components in kidney and 
brain tissue (hypothalamic 
paraventricular nucleus )
Wnt/β catenin signalling 
pathway is the main pathway 
of molecular expression of RAS 
components in brain and kidney 
tissue; local brain RAS and renal 
RAS communicate through the 
sympathetic nervous system
[26] (Zhou et al., 2019, The 
regulation effect of WNT-RAS 
signalling in hypothalamic 
paraventricular nucleus on renal 
fibrosis
[25] (Xiao et al., 2019, Wnt/β-
catenin regulates blood pressure 
and kidney injury in rats)
Angiotensin-converting 
enzyme in systemic 
circulation
Activity of ACE in systemic 
circulation increases with an 
increase of severity of CKD 
and in that way leads to further 
deterioration of kidney function
[20] (Wolke et al., 2017, Serum 
protease activity in chronic 
kidney disease patients: The 
GANI_MED renal cohort)
Chymase enzyme as an 
alternative pathway of 
activation of angiotensin II
Chymase, as an alternative 
pathway of RAS activation, 
converts angiotensin I to 
angiotensin II; blockade of this 
enzyme prevents CKD progression
[21] (Hsieh et al., 2017, Renal 
chymase-dependent pathway 
for angiotensin II formation 
mediated acute kidney injury in a 
mouse model of aristolochic acid 
I-induced acute nephropathy)
Neprilysin as an 
secondary enzymatic 
pathway for activation of 
angiotensin-(1–7)
Neprilysin, similar to ACE2 
enzyme, converts angiotensin 
II to angiotensin-(1–7) which 
binds to Mas receptors and causes 
vasodilatory and renoprotective 
effects; prevents CKD
[31] (Domenig et al., 2016, 
Neprilysin is a mediator of 
alternative renin-angiotensin-
system activation in the murine 
and human kidney)
Angiotensin receptor-
associated protein (ATRAP), 
which is associated with AT1 
receptor
ATRAP inhibits expression of 
AT1 receptor with circulating 
angiotensin II; it disables RAS 
activity in the development and 
progression of CKD
[32] (Kobayashi et al., 2017, An 
angiotensin II type 1 receptor 
binding molecule has a critical 
role in hypertension in a chronic 
kidney disease model)
Table 1. 
RAS in the pathophysiology of renal failure.
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enzymes was demonstrated, as was a reduced expression of fibronectin and type IV 
collagen—which are markers of tissue fibrosis [30].
A similar role, but with another agonist as the AT2 receptor, is played by the Mas 
receptor, which is also a part of RAS that contributes to local vasodilatation and 
has renoprotective effects. It is also known that, in normal circumstances, the Mas 
receptor is activated by angiotensin-(1–7), which is synthesized by the action of 
angiotensin-converting enzyme 2 (ACE2) on angiotensin II [31]. More recent stud-
ies of animal models with ACE2 enzyme blocking have determined the existence 
of stable levels of angiotensin-(1–7), and neprilysin was found to be the secondary 
enzymatic pathway contributing to its increase [31].
The AT1 receptor activity is regulated by a special associated protein, which 
regulates its expression and thus indirectly also regulates RAS activity. ATRAP 
inhibits the expression of the AT1 receptor and thus decreases the effect that 
circulating angiotensin II has on blood pressure levels, while also having a long-
term effect by inhibiting the secretion of TNF-alpha, whose inflammatory factors 
contribute to the development of CKD [32].
The results of the latest studies confirm the essential role that RAS plays in the 
development and progression of CKD, which emphasizes the need and paves the 
way for new research on the subject of medications and therapeutic procedures that 
could efficiently decrease the growing epidemic of patients with CKD by affecting 
RAS components [32].
5. Role in diabetes
The RAS has been implicated in the human pathophysiology of numerous 
diseases, of particular importance in the development and onset of complications 
of diabetes as one of the most lethal non-communicable metabolic diseases [33]. 
The major intracellular mechanisms responsible for the adverse effects of diabetes 
are excessive production of advanced glycation end-products (AGEs), activation 
of the hexosamine biosynthetic pathway, activation of protein kinase C (PKC), 
lipotoxicity, mitochondrial dysfunction, enhanced oxidative stress and activation 
of intracellular RAS [34]. Because of hyperglycaemia in diabetes, intracellular 
accumulation of glucose that is not oxidised by glycolysis (because of inhibition of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by reactive oxygen species 
(ROS)) is already being diverted to other metabolic pathways [34]. The result of 
GAPDH inhibition is the increased flux of glucose metabolites through four other 
metabolic pathways. These are the aldose reductase or polyol pathway, the forma-
tion of advanced glycation end-products, the formation of diacylglycerol (DAG), 
resulting in protein kinase C activation and increased flux via the hexosamine bio-
synthesis pathway (HBP), and generation of the end product uridine diphosphate 
N-acetylglucosamine (UDP-GlcNAc), a substrate used for protein glycosylation 
[35]. The polyol pathway leads to NADPH and glutathione deficiency resulting in 
massive ROS formation [34]. On the other hand, in addition to leading to the devel-
opment of insulin resistance, hyperlipidaemia also has a lipotoxic effect on cells 
[34]. Excessive fatty acid (FFA) inflow leads to increased and inefficient oxidation 
of FFA in the mitochondria with consequent generation of reactive oxygen radicals 
and exacerbation of mitochondrial dysfunction [34]. In diabetes, mitochondrial 
function decreases, and mitochondrial mass decreases, which is most likely con-
nected to a decrease in OxPhos protein expression [34]. Excessive amounts of 
ROS, AGEs, DAG and activated PKCs and post-translational O-GlcNAcylation of 
transcription factors jointly lead to activation of intracellular synthesis of AGT, 
renin and chymase and thus activation of intracellular RAS. In addition, AGEs act 
Selected Chapters from the Renin-Angiotensin System
8
via RAGE receptors that, through activation of inflammatory signalling pathways 
(TGF β, MAPK, JNK and NF-κB), lead to enhanced expression of collagen proteins 
and other extracellular matrix proteins. Together with activated RAS and activated 
PKCs isoforms by DAGs and by some lipid intermediates (e.g., ceramide, diacylg-
lycerol and acylcarnitine), there is increased inflammation, fibrosis and apoptosis 
of cells attacked by hyperglycaemia [34] (Figure 2).
6. The role of intracellular Ang II (iAngII)
In addition to the commonly known circulating RAS, there is a local tissue 
intracellular RAS that occurs in all cells that produce peptides [36]. Activation of 
the transcription factors and gene expression described in the previous paragraph 
results in the synthesis of intracellular angiotensinogen, which is converted to 
angiotensin I by renin, and becomes the intracellular angiotensin II by the proteo-
lytic action of chymase [34]. Chymase is a key proteolytic enzyme that completely 
replaces the role of extracellular angiotensin-converting enzyme within the cell 
and, unlike other alternative enzymes (tonin and cathepsin), has the highest 
substrate specificity. Intracellular Ang II levels are three times higher in diabetic 
patients than those in nondiabetic patients [37]. Intracellular Ang II has intracrine, 
autocrine, paracrine and endocrine functions [38]. iAngII by direct unidentified 
mechanisms, independent of global circulating RAS, causes an increase in oxidative 
stress and cell apoptosis and enhances the expression of intracellular components of 
RAS. Activation of AT1R via iAng II can trigger the MAPK signalling pathway (p38-
MAPK), promoting inflammation, cell proliferation and thrombosis [37]. The study 
showed that an increase in phosphorylated p53 was associated with an increase in 
iAngII, enhanced activation of AT1R and RAS-independent O-glycosylation [39]. 
Figure 2. 
Intracellular mechanism of activation and deleterious action of RAS in diabetes. ACE, angiotensin-converting 
enzyme; AGEs, advanced glycation end-products; Ang, angiotensinogen; Ang I, angiotensin I; Ang II, 
angiotensin II; ARB, angiotensin receptor blocker; AT1R, angiotensin II type 1 receptor; AT2R, angiotensin 
II type 2 receptor; DAG, diacylglycerol; FFA, free fatty acid; GAD-3P, glyceraldehyde 3-phosphate; iAng, 
intracellular angiotensin; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; NF-κB, 
nuclear factor-kappa beta; PKC, protein kinase C; RAGE, receptor for advanced glycation end-products; TCA 
cycle, tricarboxylic acid cycle; TGF-β, transforming growth factor beta.
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Also, iAng II enhances AT1R expression and decreases extracellular ACE2 expres-
sion in diabetic patients [37]. Increased expression of AT1R leads to stronger and 
negative effects of activation of AG1R [40]. ACE2 activation and AT2R activation 
are known to have protective effects on cells [38]. Direct inhibition, glycosylation 
or some other forms of protein modification leads to impaired ACE2 activity [41]. 
ACE2 catalyses the breakdown of Ang II to produce angiotensin-(1–7), which has an 
anti-inflammatory and antioxidant role [41]. In an animal model, it has been shown 
that oral administration of the recombinant-rich bacterium Lactobacillus paracasei 
(LP) can express and deliver human ACE2 to the circulation, which prevents the 
development of diabetic retinopathy and probably other forms of diabetes com-
plication [41]. This potent protective effect of AT2R is prevented by the activation 
of AT1R by either iAngII or eAngII which results in the direct inhibition of AT2R 
activity or reduced expression of AT2R[38]. On the other hand, eAngII acts through 
AT1R and AG2R, and activation of a particular receptor depends on their balance 
regulated by the indicated intracellular mechanisms [38]. Thus, activation of AT1R 
by extracellular or intracellular Ang II leads to activation of several signalling 
pathways, activation of growth factor receptors, promotion of ROS synthesis and 
other apoptotic and fibrotic responses [37]. Patients with diabetes have 10 times 
higher levels of prorenin than renin than healthy subjects, and prorenin is thought 
to contribute more to the pathogenesis of diabetic complications [40]. Also, hyper-
glycaemia induces an increase in aldosterone by activation of AT1R and an increase 
in local Ang II whose pathophysiological effects in diabetes are unknown, but are 
thought to synergize with Ang II causing inflammation, apoptosis and fibrosis [42].
7.  Influence of the RAS on pancreatic tissue, muscle tissue and adipose 
tissue
Chymase is found in all cells, and predominantly in mast cells, so we can also 
associate inflammation with the activation of RAS [43]. Activated intracellular 
RAS is thought to induce growth factor and cytokine synthesis by acting directly 
on other cells, which explains proteinuria in patients with diabetes with ACE 
inhibitors, resistance to antihypertensives in diabetics with hypertension and 
higher cardiovascular mortality in diabetics with hypertension [44]. Ang II reduces 
blood flow through beta Langerhans cells [45]. Ang II is thought to directly affect 
beta cell function and mass, promoting inflammation, oxidative stress and fibrosis 
[45]. All these effects finally lead to a decrease in insulin secretion and thus at least 
partially participate in the development of diabetes when it comes to beta cells 
[45]. Since muscle tissue accounts for about 80% of insulin-stimulated glucose 
disposal, the decrease in tissue perfusion caused by RAS directly contributes to the 
decreased glucose uptake into muscle cells [45]. On the other hand, it also leads to 
microvascular dysfunction, but all of this needs to be explored in more detail in 
the future [46]. Blockade of RAS causes overexpression of the GLUT4 transporter 
in skeletal muscle and accumulation of bradykinin that stimulates glucose uptake 
into skeletal muscle [47]. Long-term valsartan treatment reduced oxidative 
stress, NF-κB activation and TNF-alpha expression in skeletal muscle [48]. iAngII 
synthesized in adipose tissue (AT) leads to adipocyte hypertrophy, increased lipid 
synthesis and storage and inhibition of lipolysis, thereby modulating the lipid 
capacity of adipocytes to develop and worsen insulin resistance [49]. Also, Ang 
II promotes AT gene expression by enhancing the synthesis of proinflammatory 
adipokines and thus macrophage infiltration [49]. In female mice lacking the 
angiotensin II type 2 receptor (AT2R), decreased insulin sensitivity to adipose tissue 
leads to compensatory adiponectinaemia [50]. Animal model research has shown 
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that RAS in diabetic rats leads to remodelling of the sympathetic nervous system, 
increased oxidative stress and increased norepinephrine levels in the myocardium 
itself [51]. In addition to its role in controlling electrolytes, blood pressure and 
vascular tone, RAS is involved in the development of inflammation, oxidative 
stress, metabolic syndrome, diabetes and its complications [49, 52–55].
8. Use of RAS inhibitors in patients with diabetes
Therapy with angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin receptor blockers (ARB) is a mainstay of treatment for diabetes 
mellitus (DM) because they prevent the development of diabetic complications 
[56]. Also, these drugs reduce the incidence of newly acquired DM II by 22% in 
the high-risk population by improving insulin sensitivity and insulin secretion 
[49]. Unfortunately, ARB and ACE inhibitors do not block iAngII, but only the 
autocrine and paracrine effects of extracellular Ang II, while the renin inhibitor 
aliskiren blocks extracellular and intracellular Ang II synthesis; therefore, aliskiren 
of all RAS inhibitors tested has the most potent effect in inhibiting fibrosis and 
apoptosis of cells exposed [49]. Insulin treatment showed no pronounced effect on 
the inhibition of iAngII synthesis [57]. Numerous meta-analyses state that many 
RAS blockers in use today will not have an additional benefit for diabetics over 
nondiabetics [38]. Today, attention is increasingly focused on the pharmacological 
activation of angiotensin II type 2 receptor and angiotensin-converting enzyme 
2, which has been shown to reduce oxidative stress, inflammation, fibrosis and 
cell apoptosis in diabetics [57]. The protective effect has been demonstrated in 
combination therapy with activator neprilysin inhibitors (NEPi) with angiotensin-
converting enzyme 2 [57]. This combination in diabetic rats significantly 
contributes to the inhibition of inflammatory, profibrotic and apoptotic signalling 
and thus prevents the development of diabetic cardiomyopathy and nephropathy 
[58]. Concomitant activation of the angiotensin II type 1 receptor (AT1) and 
activation of glucagon-like peptide-1 (GLP-1) receptor in insulin resistance leads 
to a decrease in oxidative damage to renal function and a significant decrease in 
albuminuria [59]. Urinary angiotensinogen may serve as an important marker 
of RAS activity, which may help in the decision to initiate treatment with RAS 
inhibitors and prevent the development and progression of complications in 
patients with diabetes [59, 60]. Numerous studies are based on uncontrolled 
studies of RAS inhibition; therefore, some studies discuss the beneficial effects 
on insulin sensitivity [61–65], and controversial studies report conflicting data 
[66–69]. Dosage and duration of treatment can be important factors that can create 
controversy, and in the future, they present us with a challenge in discovering the 
beneficial effects of inhibiting potent RAS [49].
9. Role in other clinical conditions
The local renin-angiotensin system in blood vessels of the brain parenchyma 
plays a significant role in regulating blood flow. The central nervous system RAS is 
separated from the systemic circulation by the blood-brain barrier, which enables 
the homeostasis of vasoconstriction and vasodilation of blood vessels in the brain, 
independent of blood pressure changes. Components of local RAS, such as renin, 
angiotensin II, ACE and AT1 receptor, participate in the cascade that results in 
vasoconstriction and anti-inflammatory effects, while activation of the AT2 
receptor by angiotensin II and activation of the Mas receptor by angiotensin (1–7) 
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cause vasodilation and increase local brain tissue perfusion; the above has been 
demonstrated in experimental animal models [70]. Reduced levels of angiotensin-
converting enzyme 2, which produces vasoprotective angiotensin (1–7), have been 
found in clinical trials of patients with acute ischemic stroke; its levels normalise 
only in the post-acute phase of the stroke [71, 72]. As regards the above, the most 
sensational research conducted is the research on experimental animal models in 
which a reduction in the size of the ischemic penumbra after a stroke was found 
upon the use of the AT1R antagonist and the AT2R agonist; this represents a new 
treatment option for patients with ischemic stroke [71, 73]. Apart from the effect 
it has on regulating cerebral circulation, RAS also has a great effect on learning 
and memory acquisition through the activation of the AT2 receptor within the 
hippocampus and the cortex [74]. In animal models of dementia induced by 
scopolamine, simultaneous oral treatment of mice with ACE and ARB inhibitors 
slows cognitive decline [75]. It has been confirmed in clinical trials that ACE 
inhibitors and ARBs have an effect on slowing the progression of dementia caused 
by Alzheimer’s disease, cerebrovascular disease and other diseases [70].
Local RAS in the retina, which is also part of the central nervous system, plays 
a significant role in the development and progression of diabetic retinopathy. The 
effect of angiotensin II on the production of free radicals and inhibition of antioxi-
dant enzymes, which causes an increase in VEGF production, which in turn leads 
to the development of diabetic retinopathy by stimulating angiogenesis, has been 
confirmed in experimental animal models [76].
RAS plays a significant, though as yet insufficiently explored, role in the regula-
tion of physiological processes in the lung parenchyma, which is evident in the fact 
that long-term treatment by ACE inhibitors and ARBs decreases the incidence of 
inflammatory, infectious and structural diseases of the lung parenchyma [77].
Coronavirus disease 2019 (COVID-19) caused a serious pandemic, with car-
diovascular disease (10.5%) having the highest mortality rate, especially if over 70 
years of age [78]. The hypothesis of an association between the use of ACE inhibi-
tors and COVID-19 is based on the fact that the COVID-19 agent (also known as 
SARS-CoV-2) uses the SARS-CoV receptor angiotensin-converting enzyme 2 for 
entry into target alveolar epithelial cells causing pneumonia [79]. ACE2 is found in 
endothelial cells, type I and II alveolar cells of the lungs, enterocytes, basal epider-
mal cells of the skin and epithelium of the nose, oral mucosa and nasopharynx, and 
ACE2 levels decline with age and are lower in patients with chronic diseases [80]. 
Cardiovascular patients taking ACE inhibitors or AT blockers significantly increase 
mRNA expression and activity of cardiac ACE2 [81]. By binding SARS-CoV-2, ACE2 
is depleted, which inhibits the protective axis and may cause imbalances between 
the ACE/Ang II/AT1R pathway and the ACE2/Ang-(1–7)/Mas receptor in RAS, 
which may result in an increase in ACE activity and exacerbation of acute severe 
pneumonia by an increase in proinflammatory factors [82]. Animal models have 
also shown that acute ACE-induced lung injury results in increased ACE activity and 
Ang II expression, whereas ACE2 and Ang- (1–7) activities are reduced. In patients 
undergoing ACEi therapy, there is an increase in renin whose cascade response is 
directed towards the formation of ACE2 as an important balancing factor [83]. The 
binding of SARS-CoV-2 may decrease ACE2 function, leading to increased neutro-
phil infiltration into the lungs and resulting in excessive inflammation and injury 
[84]. The progression of inflammation could lead to hypoxia-induced enhanced 
expression of renin synthesis, which closes the vicious cycle, and it is clear that 
hypertension is an important risk factor in patients with COVID-19 [85, 86]. A 
meta-analysis conducted by Caldeira et al. did not highlight the protective effect of 
ACEi and ARBs [87]. A 5-year study showed that ACE administration had a higher 
risk of pneumonia than ARB administration. Low-dose lisinopril in neurological 
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dysphagia does not reduce pneumonia but increases mortality. Compared to calcium 
channel blockers, ACE inhibitors showed a lower mortality rate in patients with 
viral pneumonia [88]. Paradoxically, some authors report that chronic administra-
tion of ACE inhibitors or ARBs leads to an increase in ACE2 activity, which reduces 
the risk of infection because ACE2 dysregulation is triggered by the binding of a 
virus that increases the production of protective angiotensin-(1–7) [89]. This is 
based on the knowledge that ACEI/ARBs have shown an anti-inflammatory effect 
in the lungs, and it is suggested that they reduce the risk of pneumonia in elderly 
patients with hypertension with Parkinson’s disease, in patients after CVI and in 
patients with chronic obstructive pulmonary disease (COPD) [90]. Patients with 
viral pneumonia who retained ACE and ARB had lower mortality rates and the need 
for intubation [91]. A major Chinese study has reported that ACE2 expression level 
is not crucial for the severity of COVID-19 infection but also plays an important role 
in the immune response and viral particle count and that, given pressure control, 
ACEi and ARBs can be used in patients with new types of coronavirus pneumonia 
to reduce pulmonary inflammation and reduce patient mortality rates [80]. No 
information is currently available on the number of hospitalized COVID-19 patients 
with hypotension, but it can be considered as an important limiting factor for the 
use of ACE inhibitors or ARBs in the treatment of COVID-19 patients [89]. Thus, we 
do not yet have the most accurate information on the real impact of ACEi and ARBs 
on infectious diseases such as pneumonia. Research should be conducted as soon 
as possible to prove the hypotheses and thus reduce the risk of mortality in patients 
taking ACE inhibitors and/or AT blockers.
At its molecular level, vitamin D is a prorenin molecule transcription antagonist. 
In animal models with knockout genes for vitamin D receptors, this is reflected in 
an elevated transcription of renin-angiotensin system components, development 
of hypertension and chronic cardiac and renal failure [92]. Data obtained through 
clinical studies that investigated possible therapeutic uses of vitamin D supplemen-
tations on RAS was inconsistent. Exogenous application of vitamin D has a distinct 
effect on local kidney tissue RAS. It causes a reduction in angiotensin excretion in 
patients with chronic renal failure and/or in renal transplant recipients [93, 94]. 
However, in prospective studies, the simultaneous application of vitamin D and 
drugs that affect RAS on patients with arterial hypertension or in normotensive 
patients did not result in a decrease in arterial pressure or the difference in RAS 
component concentrations [95, 96]. The exception with regard to the previous 
statements is the prospective study carried out by Wu et al., in which a decrease in 
blood pressure values was noted after 6 months of perioral administration of high 
doses of vitamin D, as well as a decrease in atherosclerotic plaque circumference 
and thickness on epicardial blood vessels of test subjects that underwent a coronar-
ography [97]. The latest data points out an evident need for supplementary studies 
that must include a sufficient period for observation and a sufficiently large dose 
of vitamin D supplementations that would achieve a clearly notable effect on the 
observed variables.
Ghrelin, which is a peptide hormone secreted by the stomach, fulfils its 
physiological role by binding to target receptors in the central nervous system in 
which it triggers the feeling of hunger or the need for sleep by regulating hormone 
levels [98]. However, according to newly acquired data, the acylated form of this 
enzyme plays a significant, opposite role in the cardiovascular system, namely, 
in the area of the heart ventricle and aorta. Unlike RAS, which causes ischemic 
expansion and tissue degradation in cases of acute myocardial infarction, ghrelin 
has an opposite effect that is realized through its receptors. It causes a reduction 
in angiotensin-converting and proapoptotic enzyme expression, along with a 
reduction in oxidative stress [99].
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10. Therapy targeting the RAS
Knowledge of the physiology of RAS and participation in the pathophysiology of 
cardiovascular and other diseases has led to the development of drugs that have an 
effect on numerous stages of the synthesis of RAS components and their action on 
known RAS receptors. Blocking of RAS is achieved by direct inhibitors of the enzyme 
responsible for the synthesis of RAS component (renin-angiotensin-converting 
enzyme) and inhibition of receptors through which they exert their effects (angioten-
sin receptor blockers) [100]. In recent years, new RAAS components have been discov-
ered whose pathways have protective effects, which have enabled the development of 
new therapeutic targets [101]. One of the most impressive approaches in the study of 
novel therapeutic methods is the selective deletion of hepatic angiotensinogen [102].
10.1 Direct renin inhibitors
A low molecular weight non-peptide renin inhibitor that is well tolerated and 
has clinical utility is called aliskiren [103]. Clinical trials have demonstrated a strong 
antihypertensive and organoprotective (cardioprotective, renoprotective) role for 
the renin inhibitor [104, 105]. It has been shown to be very good at regulating blood 
pressure in hyperthyroid rats [106]. The use of aliskiren showed a decrease in the 
antidiuretic effect of renin [107]. This drug has a potent antifibrotic activity medi-
ated by the reduction of oxidative stress and fibrogenic cytokines in all tissues [108].
10.2 ACE inhibitors
ACE is a multifunctional enzyme with numerous biological substrates. These 
classic drugs directly inhibit the vasoconstrictive and proliferative effects of the 
already known ACE/Ang II/AT1R axis and indirectly stimulate the production of 
the vasoprotective and antiproliferative peptide Ang-(1–7) [100].
10.3 Angiotensin I receptor antagonists/blockers (ARBs)
Selective AT1 receptor blockers inhibit the effects of Ang II on AT1R. The main 
effect is the inhibition of vasoconstriction, i.e., the reduction of peripheral vascular 
resistance, without significantly affecting the heart rate [109]. Administration 
of these drugs significantly reduces cardiovascular mortality, stroke, myocardial 
infarction and the onset and development of complications of diabetes [110]. The 
consequence of AT1R blockade is an increase in the secretion of renin, ACE and 
consequently Ang II [109].
10.4 Other therapeutic compounds
10.4.1 β1 blockers
Blocking the sympathetic β1 receptor in plasma cells of the dense macula results 
in a decrease in plasma renin levels. An effect on the reduction of Ang II has been 
demonstrated. β1 blockers also reduce the conversion of prorenin to renin [111].
10.4.2 Prorenin receptor antagonist/blocker
The newly discovered prorenin receptor blocker is a decoy peptide for the 
handle region of the prorenin average (HRP) [112]. It binds competitively to the 
non- proteolytic domain of prorenin, thereby preventing its activation [113]. 
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Studies have shown that its administration reduces renal and cardiac impairment 
without affecting blood glucose levels in diabetic and antihypertensive rats [112]. 
Transgenic rat models with overexpression of the prorenin receptor showed massive 
proteinuria and glomerulosclerosis, but administration of HRP significantly sup-
pressed the production of proteinuria and glomerulosclerosis, but without affecting 
the level of circulating Ang II [114]. Another study questions the use of HRP in 
which there was no reduction in target organ damage in hypertensive rats, nor did 
the blockade affect the expression of the prorenin receptor. It is thought that HRP 
cannot block extracellular signal-regulated kinases (ERKs) that induce prorenin 
and renin and that its positive effect depends on an undefined mechanism and not 
on the antagonism of the prorenin receptor. Clearly, this receptor plays a major role 
in the human body, but its cellular biology and its impact on the cardiovascular 
system need further investigation [112].
10.4.3 Chymase inhibitors
The chymase enzyme is only active in damaged tissues resulting from the activa-
tion of intracellular RAS [115]. The chymase can convert TGF-beta and MMP-9 
precursors into their active forms that induce inflammation and fibrosis. To date, 
there are no specific results from human studies, but animal models have shown 
that inhibitors of chymase enzyme prevent vascular proliferation, myocardial fibro-
sis after cardiac infarction, development of diabetic complications, development of 
skin keloid and the occurrence of abdominal aortic aneurysm [116].
10.4.4 Angiotensin II receptor agonist
The first synthesized oral agonist was called Compound 21 (C21), which showed 
organoprotective, anti-inflammatory, antithrombotic, antifibrotic and antiapop-
totic effects in an animal model. It has a very high affinity for AT2R and a low 
affinity for AT1R [103]. C21 lowers mean arterial pressure and improves ventricular 
function after myocardial infarction [117]. It significantly stimulates the growth 
of the hippocampal neurons, and its role mediated through AT2R in enhancing 
congenital functions is further investigated [118].
10.4.5 Activation angiotensin-converting enzyme 2 and Mas receptor agonist
Activation of the protective axis of RAS by ACE2, Ang-(1–7) and Mas recep-
tors achieves beneficial vascular effects. The aim of this therapeutic target is to 
enhance the effect of ACE2, reduce the level of circulating Ang II and redirect the 
formation of Ang-(1–7), which by acting on AT2R and Mas receptors, achieves its 
protective effect. For the time being, the administration of human recombinant 
ACE2 is known to have an antihypertensive effect. ACE2 diminazene aceturate 
(DIZE) activator also reduces body weight and markers of adipogenesis and 
improves plasma lipid profile. They have a protective and pancreatic effect because 
it increases proliferation and decreases β-cell apoptosis and promotes glucose-
stimulated insulin secretion. Overexpression or expression of ACE2 enhances 
basal and insulin-stimulated glucose uptake into cells, especially hepatocytes 
and adipocytes. Another tested ACE2 activator is 1-[[2-(dimethylamino) ethyl] 
amino]-4-(hydroxymethyl)-7-[[(4-methylphenyl) sulfonyl] oxy] -9H-xanthone-9 
(XNT), which, through 2 weeks of continuous treatment, led to an improvement 
in endothelial function in hypertensive and diabetic rats by reducing oxidative 
stress. It also causes Mas receptor-mediated vasodilation [119]. In diabetic rats, 
it reduced pulmonary hypertension and significantly improved function and 
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reduced myocardial fibrosis [120]. Therefore, in addition to the antihypertensive 
effect, the use of ACE2 activator leads to beneficial metabolic effects that reduce 
the possibility of diabetes and its complications [119]. Deficiency of Mas receptor 
genes or blockade of Mas receptors in male mice results in a metabolic syndrome 
that includes hyperlipidaemia, hyperglycaemia, hyperinsulinaemia, increased 
insulin resistance, increased glucose intolerance and adiposity [121]. The use of Mas 
agonists AVE0991 in animal models showed mild cardioprotective effects and an 
effect on lowering glucose and lipid levels in the blood [122]. Another Mas agonist 
of hydroxypropyl-p-cyclodextrin (HPβCD), in addition to increasing the half-life 
of Ang-(1–7), reduced the adverse effects and magnitude of myocardial infarction, 
myocardial hypertrophy and isoproterenol-induced heart damage. The remaining 
two agonists CGEM856 and CGEM857 cause vasodilation and cardioprotection 
[123]. In addition to Mas receptors, there are probably other receptors through 
which Ang-(1–7) exerts its effects, but this needs to be revealed in the future [119]. 
Virus-mediated ACE2 gene expression, i.e., gene therapy, has shown cardioprotec-
tive and antihypertensive effects in animal models. ACE2 overexpression by gene 
therapy is not limited to the heart but shows effects in brain and lung tissue where it 
exhibits antihypertensive effects [123].
10.4.6 Analogue of Ang-(1–7)
Although it is a very attractive therapeutic target, there are very limited 
studies today because of the short lifespan of this hormone. The clinical studies 
conducted focused on the intra-arterial or intravenous administration of infu-
sions of the Ang-(1–7) analogue, which exerts its immediate vasodilatory effects. 
ACE inhibitors and angiotensin receptor antagonists, by their action, indirectly 
redirect the metabolic pathway of RAS towards the formation of increased levels 
of Ang-(1–7) [124].
10.4.7 Vaccines
The Ang I vaccine showed no antihypertensive effect, probably due to low 
antibody levels. Ang II vaccine, on the other hand, has proven to be very effective 
with a half-life of about 4 months. It was formed by covalent attachment of virus-
like particles derived from the bacteriophage Qb envelope and modified Ang II. The 
antihypertensive effect manifested on systolic and diastolic pressures mostly in the 
early morning hours compared to placebo [125]. In addition to preclinical, it has 
also been tested in clinical trials with mild side effects such as flu symptoms. The 
more recent divalent vaccine HBcAg-CE12-CQ10 has shown antihypertensive and 
renoprotective properties without immune or electrophysiological adverse effects 
and has specific binding to AT1R and L-type calcium channels [126].
10.4.8 Alamandine
Recently, a new member of the RAS family named alamandine was discovered 
on animal models. It acts on MrgD receptors and exerts vasodilatory and cardio-
protective effects similar to Ang-(1–7) [127]. Deletion of the MrgD gene at an early 
age resulted in the development of gender-independent dilated cardiomyopathy 
[128]. Endogenous alamandine is known to reduce leptin synthesis and secretion 
by activating the c-Src/p38 MAP kinase pathways, which is contrary to the action 
of Ang-(1–7) [129]. To date, no studies have been conducted on the administration 
of drugs that modulate this newly discovered component of RAS, so there is an 
opportunity to discover new therapeutic strategies in the future [127].
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10.5 Perspectives
The use of RAS-A blockers to date has not been shown to be sufficient to achieve 
the desired effects on the cardiovascular system [130]. With the realization that 
there is a protective axis within RAS, pharmacotherapy and gene therapy are 
increasingly focused on the activation of the protective components of RAS. The 
greatest challenge in the future remains to unravel the mutual mechanisms of 
regulation of the vasoconstrictive and vasoprotective axis. It is important to 
explore whether the expression of one enzyme/receptor induces the expression or 
inhibition of another, which are the mechanisms of action of the protective axis at 
the cellular level, which are the consequences of prolonged activation or inhibition 
of RAS, whether we can act more selectively on RAS and are there additional 
undetected roles and consequences of deleterious action therapies on RAS. We 
also need to further investigate the impact of gender, organ function, dosage and 
timing of administration on the targeted effect of therapy [123]. Discoveries and 
the complex modulation of RAS add a great challenge to the treatment of the most 
common diseases of humanity [130] (Figure 3).
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Figure 3. 
Influence of specific therapeutic strategies on components of the RAS. ACE, angiotensin-converting enzyme; 
AMPA, aminopeptidase A; AMPM, aminopeptidase M; Ang, angiotensin; ARBs, angiotensin receptor 
blockers; AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 receptor; AVE0991, orally active 
Mas receptor agonist; C21, Compound 21 (AT2R agonist); CGEM856 and CGEM857, orally active Mas 
receptor agonists; DIZE, ACE2 activator diminazene aceturate; HPβCD, Mas agonist hydroxypropyl-p-
cyclodextrin; HRP, decoy peptide for handle region of the prorenin prosegment; IRAP, insulin-regulated 
aminopeptidase receptor; MasR, angiotensin-(1–7) Mas receptor; MrgD, Mas-related G protein-coupled 
receptor; NEP, neprilysin; POP, prolyl oligopeptidase; PRR, prorenin receptor; TOP, thimet oligopeptidase; 
XNT, ACE2 activator xanthenone.
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